$ISCO
International Stem Cell CORP Stock $isco

$isco Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000095017023062890 Filed on November 13, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q4
Revenue	$1.889M	$1.973M	$2.430M
YoY Change	-22.26%	15.85%	31.85%
Cost Of Revenue	$863.0K	$781.0K	$1.136M
YoY Change	-24.03%	13.19%	54.56%
Gross Profit	$1.026M	$1.192M	$1.294M
YoY Change	-20.71%	17.67%	16.79%
Gross Profit Margin	54.31%	60.42%	53.25%
Selling, General & Admin	$1.284M	$1.134M	$1.108M
YoY Change	15.88%	-2.74%	-9.77%
% of Gross Profit	125.15%	95.13%	85.63%
Research & Development	$166.0K	$155.0K	$125.0K
YoY Change	32.8%	5.44%	-38.42%
% of Gross Profit	16.18%	13.0%	9.66%
Depreciation & Amortization	$48.00K	$47.00K	$52.00K
YoY Change	-7.69%	-14.55%	-22.39%
% of Gross Profit	4.68%	3.94%	4.02%
Operating Expenses	$1.450M	$1.289M	$1.233M
YoY Change	17.6%	-1.83%	-13.84%
Operating Profit	-$424.0K	-$97.00K	$61.00K
YoY Change	-795.08%	-67.67%	-118.89%
Interest Expense	-$34.00K	$34.00K	-$33.00K
YoY Change	3.03%	-197.14%	-19.51%
% of Operating Profit			-54.1%
Other Income/Expense, Net	$0.00	-$34.00K	-$5.000K
YoY Change	-100.0%	-20.93%	-138.46%
Pretax Income	-$458.0K	-$131.0K	$23.00K
YoY Change	-2091.3%	-61.81%	-106.55%
Income Tax
% Of Pretax Income
Net Earnings	-$303.0K	-$131.0K	$23.00K
YoY Change	-1417.39%	-61.81%	-106.55%
Net Earnings / Revenue	-16.04%	-6.64%	0.95%
Basic Earnings Per Share		-$0.02
Diluted Earnings Per Share	-$0.04	-$0.02	$0.00
COMMON SHARES
Basic Shares Outstanding	8.004M	8.004M	8.004M
Diluted Shares Outstanding		8.004M

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.588M	$1.430M	$742.0K
YoY Change	114.02%	114.71%	333.92%
Cash & Equivalents	$1.588M	$1.430M	$742.0K
Short-Term Investments
Other Short-Term Assets	$96.00K	$16.00K	$90.00K
YoY Change	6.67%	-69.81%	429.41%
Inventory	$1.263M	$1.317M	$1.384M
Prepaid Expenses	$80.00K	$152.0K	$64.00K
Receivables	$574.0K	$644.0K	$747.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$3.521M	$3.658M	$2.963M
YoY Change	18.83%	35.48%	26.95%
LONG-TERM ASSETS
Property, Plant & Equipment	$215.0K	$243.0K	$248.0K
YoY Change	-13.31%	-12.9%	-35.42%
Goodwill
YoY Change
Intangibles	$875.0K	$892.0K	$878.0K
YoY Change	-0.34%	-0.45%	-7.48%
Long-Term Investments
YoY Change
Other Assets	$297.0K	$320.0K	$319.0K
YoY Change	-6.9%	-20.6%	-22.38%
Total Long-Term Assets	$1.869M	$1.983M	$2.172M
YoY Change	-13.95%	-15.33%	-16.85%
TOTAL ASSETS
Total Short-Term Assets	$3.521M	$3.658M	$2.963M
Total Long-Term Assets	$1.869M	$1.983M	$2.172M
Total Assets	$5.390M	$5.641M	$5.135M
YoY Change	4.97%	11.88%	3.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$364.0K	$303.0K	$322.0K
YoY Change	13.04%	-19.84%	-36.61%
Accrued Expenses	$485.0K	$442.0K	$508.0K
YoY Change	-4.53%	-6.95%	25.74%
Deferred Revenue
YoY Change
Short-Term Debt	$3.457M	$3.424M	$3.325M
YoY Change	3.97%	4.04%	12.98%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.832M	$4.682M	$4.635M
YoY Change	4.25%	1.5%	8.19%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$445.0K	$518.0K	$720.0K
YoY Change	-38.19%	-33.67%	-24.21%
Total Long-Term Liabilities	$445.0K	$518.0K	$720.0K
YoY Change	-38.19%	-33.67%	-24.21%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.832M	$4.682M	$4.635M
Total Long-Term Liabilities	$445.0K	$518.0K	$720.0K
Total Liabilities	$5.277M	$5.200M	$5.355M
YoY Change	-1.46%	-3.6%	2.31%
SHAREHOLDERS EQUITY
Retained Earnings	-$110.5M	-$110.0M	-$110.3M
YoY Change	0.18%	-0.36%	0.26%
Common Stock	$8.000K	$8.000K	$8.000K
YoY Change	0.0%	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$4.187M	-$3.859M	-$4.520M
YoY Change
Total Liabilities & Shareholders Equity	$5.390M	$5.641M	$5.135M
YoY Change	4.97%	11.88%	3.82%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q4
OPERATING ACTIVITIES
Net Income	-$303.0K	-$131.0K	$23.00K
YoY Change	-1417.39%	-61.81%	-106.55%
Depreciation, Depletion And Amortization	$48.00K	$47.00K	$52.00K
YoY Change	-7.69%	-14.55%	-22.39%
Cash From Operating Activities	$161.0K	$62.00K	$79.00K
YoY Change	103.8%	-26.19%	-125.0%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$14.00K	$3.000K
YoY Change	-100.0%	-450.0%	-116.67%
Acquisitions
YoY Change
Other Investing Activities	-$3.000K
YoY Change
Cash From Investing Activities	-$3.000K	-$14.00K	-$3.000K
YoY Change	0.0%	250.0%	-83.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	0.000	0.000
YoY Change
NET CHANGE
Cash From Operating Activities	161.0K	62.00K	79.00K
Cash From Investing Activities	-3.000K	-14.00K	-3.000K
Cash From Financing Activities	0.000	0.000	0.000
Net Change In Cash	158.0K	48.00K	76.00K
YoY Change	107.89%	-40.0%	-122.75%
FREE CASH FLOW
Cash From Operating Activities	$161.0K	$62.00K	$79.00K
Capital Expenditures	$0.00	$14.00K	$3.000K
Free Cash Flow	$161.0K	$48.00K	$76.00K
YoY Change	111.84%	-45.45%	-125.5%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Central Index Key EntityCentralIndexKey	0001355790
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q3	us-gaap	Notes Payable Current Related Party Type Extensible Enumeration NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2022Q4	us-gaap	Notes Payable Current Related Party Type Extensible Enumeration NotesPayableCurrentRelatedPartyTypeExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q3	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2023#ProductMember
CY2022Q3	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2023#ProductMember
	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2023#ProductMember
	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2023#ProductMember
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	0-51891
	dei	Entity Registrant Name EntityRegistrantName	INTERNATIONAL STEM CELL CORPORATION
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-4494098
	dei	Entity Address Address Line1 EntityAddressAddressLine1	9745 Businesspark Ave
	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92131
	dei	City Area Code CityAreaCode	760
	dei	Local Phone Number LocalPhoneNumber	940-6383
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8004389
CY2023Q3	us-gaap	Cash Cash	1430000
CY2022Q4	us-gaap	Cash Cash	742000
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	644000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	747000
CY2023Q3	us-gaap	Inventory Net InventoryNet	1317000
CY2022Q4	us-gaap	Inventory Net InventoryNet	1384000
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	267000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	90000
CY2023Q3	us-gaap	Assets Current AssetsCurrent	3658000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	2963000
CY2023Q3	us-gaap	Inventory Noncurrent InventoryNoncurrent	288000
CY2022Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	286000
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	243000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	248000
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	817000
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	878000
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	603000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	727000
CY2023Q3	isco	Deposits And Other Assets DepositsAndOtherAssets	32000
CY2022Q4	isco	Deposits And Other Assets DepositsAndOtherAssets	33000
CY2023Q3	us-gaap	Assets Assets	5641000
CY2022Q4	us-gaap	Assets Assets	5135000
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	303000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	322000
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	442000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	508000
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	263000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	230000
CY2023Q3	isco	Advances From Nonaffiliated Collaboration AdvancesFromNonaffiliatedCollaboration	250000
CY2022Q4	isco	Advances From Nonaffiliated Collaboration AdvancesFromNonaffiliatedCollaboration	250000
CY2023Q3	us-gaap	Notes Payable Current NotesPayableCurrent	3424000
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	3325000
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	4682000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4635000
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	518000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	720000
CY2023Q3	us-gaap	Liabilities Liabilities	5200000
CY2022Q4	us-gaap	Liabilities Liabilities	5355000
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8004389
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8004389
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8004389
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8004389
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	8000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	8000
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	106146000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	105812000
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-110018000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-110345000
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-3859000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-4520000
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5641000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5135000
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1973000
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1703000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5900000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5750000
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	781000
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	690000
	us-gaap	Cost Of Revenue CostOfRevenue	2318000
	us-gaap	Cost Of Revenue CostOfRevenue	2133000
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	832000
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	808000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2550000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2512000
CY2023Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	302000
CY2022Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	358000
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	926000
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	982000
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	155000
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	147000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	345000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	367000
CY2023Q3	us-gaap	Costs And Expenses CostsAndExpenses	2070000
CY2022Q3	us-gaap	Costs And Expenses CostsAndExpenses	2003000
	us-gaap	Costs And Expenses CostsAndExpenses	6139000
	us-gaap	Costs And Expenses CostsAndExpenses	5994000
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-97000
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-300000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-239000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-244000
	isco	Employee Retention Credit EmployeeRetentionCredit	663000
CY2023Q3	us-gaap	Interest Expense InterestExpense	34000
CY2022Q3	us-gaap	Interest Expense InterestExpense	35000
	us-gaap	Interest Expense InterestExpense	105000
	us-gaap	Interest Expense InterestExpense	102000
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-8000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	8000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-8000
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-34000
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-43000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	566000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-110000
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-131000
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-343000
	us-gaap	Net Income Loss NetIncomeLoss	327000
	us-gaap	Net Income Loss NetIncomeLoss	-354000
	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	155000
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-131000
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-343000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	172000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-354000
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8004389
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8004389
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8004389
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8004389
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8004389
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8004389
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8004389
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8004389
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-4520000
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	108000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-34000
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-4446000
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	108000
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	492000
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-3846000
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	118000
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-131000
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-3859000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-4588000
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	91000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-9000
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-4506000
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	90000
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-2000
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-4418000
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	109000
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-343000
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-4652000
	us-gaap	Profit Loss ProfitLoss	327000
	us-gaap	Profit Loss ProfitLoss	-354000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	146000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	166000
	isco	Non Cash Operating Lease Expense NonCashOperatingLeaseExpense	124000
	isco	Non Cash Operating Lease Expense NonCashOperatingLeaseExpense	104000
	us-gaap	Share Based Compensation ShareBasedCompensation	334000
	us-gaap	Share Based Compensation ShareBasedCompensation	290000
	isco	Interest Expense On Related Party Note Payable InterestExpenseOnRelatedPartyNotePayable	99000
	isco	Interest Expense On Related Party Note Payable InterestExpenseOnRelatedPartyNotePayable	98000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-103000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-417000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-65000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	228000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	177000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	57000
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-1000
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-5000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-19000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-130000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-66000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	71000
	isco	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-169000
	isco	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-129000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	768000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	253000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	80000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1000
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	7000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-80000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-8000
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	250000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	250000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	688000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	495000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	742000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	171000
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1430000
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	666000
	us-gaap	Interest Paid Net InterestPaidNet	5000
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-110000000
	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Significant estimates include patent life (remaining legal life versus remaining useful life), inventory carrying values, and the fair value of stock option grants using the Black-Scholes option valuation model. By their nature, estimates are subject to an inherent degree of uncertainty and actual results could differ from these estimates.</span></p>
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	3
CY2023Q3	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P15Y
	us-gaap	Revenue Performance Obligation Description Of Payment Terms RevenuePerformanceObligationDescriptionOfPaymentTerms	The Company's revenue consists primarily of sales of products from its two revenue-generating operating segments, the biomedical market (LCT) and anti-aging market (LSC). The anti-aging market sells products solely through the ecommerce channel. The biomedical market sells primary human cell research products with two product categories, cells and media, which are sold both domestically and internationally. The biomedical market also offers performance of quality control (QC) testing services. No revenue from services was earned during the three and nine months ended September 30, 2023 and 2022.
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2
CY2023Q3	isco	Number Of Products Categories NumberOfProductsCategories	2
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	644000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	747000
CY2023Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
CY2022Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
	isco	Reduction In Research And Development Expenses ReductionInResearchAndDevelopmentExpenses	99000
	isco	Reduction In Research And Development Expenses ReductionInResearchAndDevelopmentExpenses	80000
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-131000
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-343000
	us-gaap	Net Income Loss NetIncomeLoss	327000
	us-gaap	Net Income Loss NetIncomeLoss	-354000
	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	155000
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-131000
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-131000
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-343000
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-343000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	172000
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	172000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-354000
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-354000
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8004389
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8004389
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8004389
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8004389
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8004389
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8004389
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8004389
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8004389
CY2023Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.02
CY2023Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.02
CY2022Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.04
CY2022Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.04
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.02
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.02
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.04
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.04
CY2023Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16528759
CY2022Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12935014
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15057204
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12935014
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Customer Concentrations</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the three months ended September 30, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> customer accounted for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">47</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">34</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of consolidated revenues, respectively. For the nine months ended September 30, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> customer accounted for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">46</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">43</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of consolidated revenues, respectively. No other single customer accounted for more than 10% of revenues for the periods then ended for any segment.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of September 30, 2023 and December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the same customer accounted for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">40</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">73</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of accounts receivable, net, respectively. As of September 30, 2023, one additional customer accounted for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">accounts</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">receivable, </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">net. No other single customer accounted for more than 10% of accounts receivable, net as of the periods then ended for any segment.</span></p>
CY2023Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	574000
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	615000
CY2023Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	484000
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	498000
CY2023Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1224000
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1194000
CY2023Q3	us-gaap	Inventory Gross InventoryGross	2282000
CY2022Q4	us-gaap	Inventory Gross InventoryGross	2307000
CY2023Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	677000
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	637000
CY2023Q3	isco	Inventory Net Current And Noncurrent InventoryNetCurrentAndNoncurrent	1605000
CY2022Q4	isco	Inventory Net Current And Noncurrent InventoryNetCurrentAndNoncurrent	1670000
CY2023Q3	us-gaap	Inventory Net InventoryNet	1317000
CY2022Q4	us-gaap	Inventory Net InventoryNet	1384000
CY2023Q3	us-gaap	Inventory Noncurrent InventoryNoncurrent	288000
CY2022Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	286000
CY2023Q3	isco	Inventory Net Current And Noncurrent InventoryNetCurrentAndNoncurrent	1605000
CY2022Q4	isco	Inventory Net Current And Noncurrent InventoryNetCurrentAndNoncurrent	1670000
CY2023Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	152000
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	64000
CY2023Q3	isco	Australian Research And Development Tax Credit AustralianResearchAndDevelopmentTaxCredit	99000
CY2023Q3	us-gaap	Other Assets Current OtherAssetsCurrent	16000
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	26000
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	267000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	90000
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2542000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2467000
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2299000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2219000
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	243000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	248000
CY2023Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	27000
CY2022Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	34000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	85000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	106000
CY2023Q3	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	1286000
CY2022Q4	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	1286000
CY2023Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	544000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	483000
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	742000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	803000
CY2023Q3	us-gaap	Indefinite Lived Trademarks IndefiniteLivedTrademarks	75000
CY2022Q4	us-gaap	Indefinite Lived Trademarks IndefiniteLivedTrademarks	75000
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	817000
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	878000
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	20000
CY2022Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	21000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	61000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	60000
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
	us-gaap	Dividends Preferred Stock DividendsPreferredStock	0
CY2023Q3	us-gaap	Preferred Stock Convertible Conversion Ratio PreferredStockConvertibleConversionRatio	1
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	118000
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	109000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	334000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	290000
CY2023Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	560000
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y7M9D
CY2023Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	16754269
CY2021Q4	isco	Lease Costs Incurred Percentage LeaseCostsIncurredPercentage	0.40
	isco	Number Of Operating Leases NumberOfOperatingLeases	3
CY2021Q4	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2026-12-31
CY2021Q4	us-gaap	Operating Lease Expense OperatingLeaseExpense	11000
CY2021Q4	isco	Percentage Of Increase Rent Per Annum Over Lease Term PercentageOfIncreaseRentPerAnnumOverLeaseTerm	0.035
CY2021Q4	isco	Percentage Of Base Rent Abated PercentageOfBaseRentAbated	0.50
CY2021Q4	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2026-12-31
CY2021Q4	us-gaap	Operating Lease Expense OperatingLeaseExpense	4000
CY2022Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	71000
CY2023Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	71000
	us-gaap	Operating Lease Cost OperatingLeaseCost	213000
	us-gaap	Operating Lease Cost OperatingLeaseCost	213000
CY2023Q3	isco	Finance Leases FinanceLeases	0
CY2022Q4	isco	Finance Leases FinanceLeases	0
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	84000
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	349000
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	360000
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	119000
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	912000
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	131000
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	781000
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	263000
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	518000
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	3
	isco	Number Of Business Units NumberOfBusinessUnits	2
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1973000
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1703000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5900000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5750000
CY2023Q3	us-gaap	Costs And Expenses CostsAndExpenses	2070000
CY2022Q3	us-gaap	Costs And Expenses CostsAndExpenses	2003000
	us-gaap	Costs And Expenses CostsAndExpenses	6139000
	us-gaap	Costs And Expenses CostsAndExpenses	5994000
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-97000
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-300000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-239000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-244000
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-34000
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-43000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	566000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-110000
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-131000
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-343000
	us-gaap	Net Income Loss NetIncomeLoss	327000
	us-gaap	Net Income Loss NetIncomeLoss	-354000

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0000950170-23-062890-index-headers.html	Edgar Link	pending
0000950170-23-062890-index.html	Edgar Link	pending
0000950170-23-062890.txt	Edgar Link	pending
0000950170-23-062890-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
isco-20230930.htm	Edgar Link	pending
isco-20230930.xsd	Edgar Link	pending
isco-ex31_1.htm	Edgar Link	pending
isco-ex31_2.htm	Edgar Link	pending
isco-ex32_1.htm	Edgar Link	pending
isco-ex32_2.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
isco-20230930_cal.xml	Edgar Link	unprocessable
isco-20230930_def.xml	Edgar Link	unprocessable
isco-20230930_lab.xml	Edgar Link	unprocessable
isco-20230930_pre.xml	Edgar Link	unprocessable
isco-20230930_htm.xml	Edgar Link	completed
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ISCO
International Stem Cell CORP Stock $isco

2023 Q4 Form 10-Q Financial Statement

#000095017023062890 Filed on November 13, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ISCO International Stem Cell CORP Stock $isco

2023 Q4 Form 10-Q Financial Statement

#000095017023062890 Filed on November 13, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ISCO
International Stem Cell CORP Stock $isco